Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: no intervention.
- Who it may be relevant to
- Registry conditions: Gaucher Disease. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This is an observational study intended to generate preliminary data to understand how lysosomal dysfunction can affect the biogenesis of extracellular vesicles, its content and function. The primary objective of the proposed project is to decipher how extracellular vesicle (EV) biogenesis and its role in intercellular communication can be impaired as a consequence of defects in lysosomal function. Collectively these defects in EV biogenesis and function can contribute to the neuroinflammation observed in lysosomal storage diseases. Since EVs can cross the blood-brain barrier, their characterization may be valuable in identifying novel biomarkers. In the presence of a GBA1 mutation, the decrease in GCase activity will lower overall lysosome function and increase the secretion of EVs. Further, there will be differences in EV size, its cargo including lipids, RNA and proteins and their aggregates. In comparison to healthy controls, EVs isolated from patients with Gaucher disease (GD) and GBA1 carriers is hypothesized to show significant differences in terms of its characteristics and content, which can contribute to our understanding of the link between lysosomes and neurological disease.
Interventions
- Other no intervention
no intervention, this is an observational study
Primary outcome measures
- EVs quantity [Time frame: baseline]
- EVs quantity [Time frame: 3months]
- EVs size [Time frame: baseline]
- EVs size [Time frame: 3months]
- EVs content [Time frame: baseline]
- EVs content [Time frame: 3months]
Eligibility criteria
Inclusion criteria
- Age between 18-80yrs
- Restricted to participants who are untreated, obligate carriers and healthy controls.
- Participants with GD should have confirmed GD diagnosis, mutation confirmed for carriers and healthy controls confirmed to have no GBA1 mutation by gene sequencing.
Exclusion criteria
- Exclude participants who have any hematological malignancy or other uncontrolled comorbid conditions.
- Exclude participants who are currently on therapy for their GD
- Exclude participants who have any hematological malignancy or other uncontrolled comorbid conditions.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Case-control
Study locations
United States · 1 center
- University of Minnesota — Minneapolis
Identifiers
NCT: NCT05843552 · EV